2. Academic Validation
  3. Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists

Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists

  • Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9. doi: 10.1016/j.bmcl.2004.06.032.
Laura C McAtee 1,  Steven W Sutton,  Dale A Rudolph,  Xiaobing Li,  Leah E Aluisio,  Victor K Phuong,  Curt A Dvorak,  Timothy W Lovenberg,  Nicholas I Carruthers,  Todd K Jones
Affiliations

Affiliation

  • 1 Johnson and Johnson Pharmaceutical Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA.
PMID: 15261275 DOI: 10.1016/j.bmcl.2004.06.032
Abstract

Orexins, also termed hypocretins, consist of two neuropeptide agonists (orexin A and B) interacting with two known G-protein coupled receptors (OX(1)R and OX(2)R). In addition to other biological functions, the orexin-2 receptor is thought to be an important modulator of sleep and wakefulness. Herein we describe a series of novel, selective OX(2)R antagonists consisting of substituted 4-phenyl-[1,3]dioxanes. One such antagonist is compound 9, 1-(2,4-dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-[1,3]dioxan-5-yl)-urea, which is bound by the OX(2)R with a pK(i) of 8.3, has a pK(b) of 7.9, and is 600-fold selective for the OX(2)R over the OX(1)R.

Figures
Products